Abstract
We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Current Vascular Pharmacology
Title:Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Volume: 14 Issue: 4
Author(s): Mohammed Fakhry, Khalid Al-Rasadi, Khamis Al-Hashmi, Khalid Al-Waili, Raul D. Santos, Haitham Amin, Fahad O.A.S. Baslaib, Omar Al-Hallaq, Obaid Al-Jassim, Afzal H. Yusufali, Abdel R. Medani, Hossam Elghetany, Ibrahim Al-Zakwani, Akram Al-Khadra, Othman Metwally, Khalid Al-Nemer, Faisal Al-Anazi, Shorook Al-Herz, Mahmoud Al-Awadhi, Omer Al-Tamimi, Abdullah Shehab, Ali T. Al-Hinai, Mohamed Arafah and Wael Al-Mahmeed
Affiliation:
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Abstract: We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Export Options
About this article
Cite this article as:
Fakhry Mohammed, Al-Rasadi Khalid, Al-Hashmi Khamis, Al-Waili Khalid, Santos D. Raul, Amin Haitham, Baslaib O.A.S. Fahad, Al-Hallaq Omar, Al-Jassim Obaid, Yusufali H. Afzal, Medani R. Abdel, Elghetany Hossam, Al-Zakwani Ibrahim, Al-Khadra Akram, Metwally Othman, Al-Nemer Khalid, Al-Anazi Faisal, Al-Herz Shorook, Al-Awadhi Mahmoud, Al-Tamimi Omer, Shehab Abdullah, Al-Hinai T. Ali, Arafah Mohamed and Al-Mahmeed Wael, Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf, Current Vascular Pharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570161113666151026115921
DOI https://dx.doi.org/10.2174/1570161113666151026115921 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design Waist-to-Hip Ratio (WHR) is Conversely Correlated to LAMP-2 Gene Expression Level: A Predictor for Lysosomal Lipid Entrance System
Current Nutrition & Food Science ATP-Sensitive K+ Channel Openers: Old Drugs with New Clinical Benefits for the Heart
Current Vascular Pharmacology Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Flavonoids for Allergic Diseases: Present Evidence and Future Perspective
Current Pharmaceutical Design PGD and Prenatal Diagnosis: Comparison and Review in Different Genetic Disorders
Current Women`s Health Reviews Chronic Inflammatory Disorders and Accelerated Atherosclerosis: Chronic Kidney Disease
Current Pharmaceutical Design Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology The Links Between Sleep Apnea and Chronic Kidney Disease
Current Respiratory Medicine Reviews Evaluation of Clinical Efficacy of Fasudil for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Conivaptan: Potential Therapeutic Implications in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Chemistory of Fibrates
Current Chemical Biology A Review of Patents Relating to Therapeutic Angiogenesis Using Endothelial Progenitors and Other Vasculogenesis-Related Cell Types
Recent Patents on Regenerative Medicine